相关实验视频
Updated: Jul 19, 2026

08:41
Investigating the Phagocytosis of Leishmania using Confocal Microscopy
Published on: July 29, 2021
3.7K
在Leishmania infantum中对E2结合酶LinfUbc13的分子表征
Eduardo Vagner Rodrigues da Silva1, Caroline Torres2, Hariel Nemamiah Escolarique Ribeiro1
1Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Archives of biochemistry and biophysics
|December 17, 2024
概括
莱什马尼亚婴儿UBC13 (LinfUBC13) 是一种重要的E2酶,对寄生虫的发展至关重要. 它在无处不在的保存结构和功能突出显示了内脏莱什曼病的潜在治疗点.
科学领域:
- 分子寄生虫学 分子寄生虫学
- 生物化学 生物化学
- 细胞生物学 细胞生物学
背景情况:
- 无素-蛋白酶体系统对于寄生虫的平衡至关重要,也是莱什曼尼cidal 药物的目标.
- 婴儿莱什马尼亚会导致内脏莱什马尼亚症,这是一种严重且可能致命的疾病.
- 了解Leishmania的无处不在是理解leishmaniasis的关键.
研究的目的:
- 为了鉴定Leishmania infantum中LinfUBC13基因和蛋白质的特征.
- 调查LinfUBC13在寄生虫的无处可见化过程中的作用.
- 探索潜在的治疗策略来对抗莱什曼病.
主要方法:
- 林夫UBC13.的基因表征和序列分析.
- 与人类UBE2D蛋白质的结构比较.
- 再组合LinfUbc13.的表达和净化.
- 在实验室中使用E1,E3酶 (HDM2) 和p53.3的ubiquitination测试.
- 在寄生虫内的亚细胞局部化研究.
主要成果:
- LinfUBC13与人类UBE2D蛋白具有高序列相同性 (72-74%) 和结构相似性.
- 保存的催化残留物 (Cys86,HPN动机) 证实了乌比奎结合活性.
- 再组合的LinfUbc13从E1接收乌比奎丁,并通过HDM2.2将其转移到p53.
- LinfUbc13位于莱什曼尼亚婴儿菌的细胞质中.
- 该基因是必不可少的,因为不能产生零突变.
结论:
- LinfUbc13是一个功能性的E2无素-结合酶在Leishmania婴儿.
- 在Leishmania和Homo sapiens之间保存了无处不在的蛋白质酶系统.
- LinfUbc13在寄生虫发育中起着至关重要的作用,是潜在的药物标.
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

